Pioglitazone attenuates prostatic enlargement in diet‐induced insulin‐resistant rats by altering lipid distribution and hyperinsulinaemia
Open Access
- 19 August 2010
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 161 (8) , 1708-1721
Abstract
BACKGROUND AND PURPOSE Increased incidence of benign prostatic hyperplasia among insulin‐resistant individuals suggests a role for hyperinsulinaemia in prostatic enlargement. We have already reported increased cell proliferation and enlargement of prostate gland in insulin‐resistant rats. The present study aimed to elucidate the molecular mechanisms underlying the reversal of prostatic enlargement in insulin‐resistant rats by the peroxisome proliferator‐activated receptor γ agonist pioglitazone.EXPERIMENTAL APPROACH Sprague–Dawley rats were fed a normal pellet or a high‐fat diet for 12 weeks with or without pioglitazone (20 mg·kg−1). Subgroups of animals fed different diets were castrated. Effects of dietary manipulation and pioglitazone were measured on insulin sensitivity, lipid distribution, cell proliferation and apoptosis.KEY RESULTS A high‐fat diet led to the accumulation of fat in non‐adipose tissues, insulin resistance, compensatory hyperinsulinaemia and prostatic enlargement in rats. Pioglitazone treatment altered fat distribution, improved insulin sensitivity and normalized lipid and insulin level in rats on the high‐fat diet. The improved metabolic parameters led to decreased cellular proliferation and increased apoptosis in the prostate gland. High‐fat diet feeding and pioglitazone treatment did not change plasma testosterone levels. However, significant prostatic atrophy was observed in castrated rats irrespective of dietary intervention.CONCLUSIONS AND IMPLICATIONS Our results show a previously unexplored therapeutic potential of pioglitazone for prostatic enlargement under insulin‐resistant condition and further suggest that targeting distribution of lipid from non‐adipose tissue to adipose tissue and insulin signalling could be new strategies for the treatment of benign prostatic hyperplasia.Keywords
This publication has 46 references indexed in Scilit:
- Guide to Receptors and Channels (GRAC), 5th editionBritish Journal of Pharmacology, 2011
- RETRACTED: Pioglitazone improves lipid and insulin levels in overweight rats on a high cholesterol and fructose diet by decreasing hepatic inflammationBritish Journal of Pharmacology, 2010
- Guide to Receptors and Channels (GRAC), 4th editionBritish Journal of Pharmacology, 2009
- Inhibition of human insulin gene transcription by peroxisome proliferator‐activated receptor γ and thiazolidinedione oral antidiabetic drugsBritish Journal of Pharmacology, 2009
- Combining a dipeptidyl peptidase‐4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and β‐cell function in db/db miceBritish Journal of Pharmacology, 2009
- A role for epithelial-mesenchymal transition in the etiology of benign prostatic hyperplasiaProceedings of the National Academy of Sciences, 2009
- Pioglitazone opposes neurogenic vascular dysfunction associated with chronic hyperinsulinaemiaBritish Journal of Pharmacology, 2008
- Thiazolidinediones: effects on insulin resistance and the cardiovascular systemBritish Journal of Pharmacology, 2008
- Increased prostate cell proliferation and loss of cell differentiation in mice lacking prostate epithelial androgen receptorProceedings of the National Academy of Sciences, 2007
- Metabolic Factors Associated with Benign Prostatic HyperplasiaThe Journal of Clinical Endocrinology & Metabolism, 2006